CluenexExelixis EXEL
Exelixis scores excellent on business quality (8.4 of 10). Here is why, in plain words, and what our sealed record shows.
Why it matters
- What Exelixis does
Exelixis develops and commercializes oncology medicines, generating revenue primarily from its flagship cancer drug Cabometyx through commercial sales and collaboration partnerships with major pharmaceutical licensees.
- What it does best
Exelixis excels at commercializing oncology assets with world-class efficiency, boasting a gross margin of 96.5% that outpaces peers like Insm's 83.4%. This elite margin reflects deep patent protection and lucrative licensing structures that competitors struggle to replicate.
- The main risk
Concentration risk around Cabometyx remains high, leaving the top line vulnerable to patent challenges, regulatory delays in label expansions, or competitive trial readouts in renal cell carcinoma.
Quality, check by check
Scored against its own industry, from company filings.
Operating margin sits at 39.9% while free cash flow margin reaches 99.0%, both expanding rapidly as high-margin product sales scale without heavy capital intensity.
A robust intellectual property portfolio locks in oncology partners and prescribers, backed by a gross margin in the top decile of its sector at 96.5%.
Revenue grew 7.0% to $2.4B, ticking up from prior years but remaining modest as the core oncology portfolio matures past its hyper-growth phase.
Zero total debt and $1.1B in cash mean debt costs are nonexistent. Free cash flow surged to $1.2B, showing the balance sheet is getting significantly stronger.
Insiders
Executives and directors, from SEC Form 4 filings we read ourselves. Open market trades only; grants, option exercises and pre-planned sales left out.
No open market buys or unplanned sales by executives or directors.
Our sealed record on EXEL
Verdicts appear here 30 days after we publish them; members see today's. Each one is in the nightly ledger, fingerprinted the night it was made.
The first sealed verdicts appear here on Oct 11, 2026.
Questions
Exelixis scores excellent on the Cluenex quality check (8.4 of 10), measured against its own industry. Profitability is strong, moat strong, growth steady and financial health strong.
In the last 90 days of SEC Form 4 filings: No open market buys or unplanned sales by executives or directors.
Nov 3, 2026.
See EXEL today
- Today's verdict on EXEL, and why
- Fair value with cautious, base and optimistic cases
- The exact price that would change the verdict
- Which stocks each signal names, the night it fires
Cite this page: Cluenex, “Exelixis (EXEL)”, https://cluenex.com/stocks/exel/, data as of Oct 10, 2026.